The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Androgen receptor expression in breast cancer in relation to molecular phenotype: results from the Nurses' Health Study
Open accessAbstract
Previous studies have demonstrated that androgen receptor is expressed in many breast cancers, but its expression in relation to the various breast cancer subtypes as defined by molecular profiling has not been studied in detail. We constructed tissue microarrays from 3093 breast cancers that developed in women enrolled in the Nurses' Health Study. Tissue microarray sections were immunostained for estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), cytokeratin 5/6, epidermal growth factor receptor (EGFR) and androgen receptor (ER). Immunostain results were used to categorize each cancer as luminal A or B, HER2 and basal like. The relationships between androgen receptor expression and molecular subtype were analyzed. Overall, 77% of the invasive breast carcinomas were androgen receptor positive. Among 2171 invasive cancers, 64% were luminal A, 15% luminal B, 6% HER2 and 11% basal like. The frequency of androgen receptor expression varied significantly across the molecular phenotypes (P<0.0001). In particular, androgen receptor expression was commonly observed in luminal A (91%) and B (68%) cancers, but was less frequently seen in HER2 cancers (59%). Despite being defined by the absence of ER and PR expression and being considered hormonally unresponsive, 32% of basal-like cancers expressed androgen receptor. Among 246 cases of ductal carcinoma in situ, 86% were androgen receptor positive, but the frequency of androgen receptor expression differed significantly across the molecular phenotypes (P=0.001), and high nuclear grade lesions were less likely to be androgen receptor positive compared with lower-grade lesions. Androgen receptor expression is most commonly seen in luminal A and B invasive breast cancers. However, expression of androgen receptor is also seen in approximately one-third of basal-like cancers, providing further evidence that basal-like cancers represent a heterogeneous group. Our findings raise the possibility that targeting the androgen receptor pathway may represent a novel therapeutic approach to the management of patients with basal-like cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sørlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 10,938
Repeated observation of breast tumor subtypes in independent gene expression data sets
Sørlie, T., Tibshirani, R., Parker, J., Hastie, T., Marron, J. S., Nobel, A., Deng, S., Johnsen, H., Pesich, R., Geisler, S., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0932692100 · Cited by 5,429
Nielsen, T. O., Hsu, F. D., Jensen, K., Cheang, M., Karaca, G., Hu, Z., Hernandez-Boussard, T., Livasy, C., Cowan, D., Dressler, L., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0220 · Cited by 2,663
Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer
Cheang, M. C. U., Chia, S. K., Voduc, D., Gao, D., Leung, S., Snider, J., Watson, M., Davies, S., Bernard, P. S., Parker, J. S., et al. (2009) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp082 · Cited by 2,249
The Endogenous Hormones and Breast Cancer Collaborative Group (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.8.606 · Cited by 1,793
Distinctive gene expression patterns in human mammary epithelial cells and breast cancers
Perou, C. M., Jeffrey, S. S., van de Rijn, M., Rees, C. A., Eisen, M. B., Ross, D. T., Pergamenschikov, A., Williams, C. F., Zhu, S. X., Lee, J. C. F., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.16.9212 · Cited by 1,402
Prognostic markers in triple‐negative breast cancer
Rakha, E. A., El‐Sayed, M. E., Green, A. R., Lee, A. H. S., Robertson, J. F., & Ellis, I. O. (2007) · Cancer · doi:10.1002/cncr.22381 · Cited by 1,283
Breast Cancer Subtypes and the Risk of Local and Regional Relapse
Voduc, K. D., Cheang, M. C. U., Tyldesley, S., Gelmon, K., Nielsen, T. O., & Kennecke, H. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.9284 · Cited by 1,243
Blows, F. M., Driver, K. E., Schmidt, M. K., Broeks, A., van Leeuwen, F. E., Wesseling, J., Cheang, M. C., Gelmon, K., Nielsen, T. O., Blomqvist, C., et al. (2010) · PLoS Medicine · doi:10.1371/journal.pmed.1000279 · Cited by 1,116
Molecular Classification and Molecular Forecasting of Breast Cancer: Ready for Clinical Application?
Brenton, J. D., Carey, L. A., Ahmed, A. A., & Caldas, C. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.3845 · Cited by 953
Nielsen, T. O., Parker, J. S., Leung, S., Voduc, D., Ebbert, M., Vickery, T., Davies, S. R., Snider, J., Stijleman, I. J., Reed, J., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1282 · Cited by 801
Identification of molecular apocrine breast tumours by microarray analysis
Farmer, P., Bonnefoi, H., Becette, V., Tubiana-Hulin, M., Fumoleau, P., Larsimont, D., MacGrogan, G., Bergh, J., Cameron, D., Goldstein, D., et al. (2005) · Oncogene · doi:10.1038/sj.onc.1208561 · Cited by 785
Etiology of Hormone Receptor–Defined Breast Cancer: A Systematic Review of the Literature
Althuis, M. D., Fergenbaum, J. H., Garcia-Closas, M., Brinton, L. A., Madigan, M. P., & Sherman, M. E. (2004) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.1558.13.10 · Cited by 628
Abd El‐Rehim, D. M., Ball, G., Pinder, S. E., Rakha, E., Paish, C., Robertson, J. F. R., Macmillan, D., Blamey, R. W., & Ellis, I. O. (2005) · International Journal of Cancer · doi:10.1002/ijc.21004 · Cited by 606
Expression of luminal and basal cytokeratins in human breast carcinoma
Abd El‐Rehim, D. M., Pinder, S. E., Paish, C. E., Bell, J., Blamey, R., Robertson, J. F., Nicholson, R. I., & Ellis, I. O. (2004) · The Journal of Pathology · doi:10.1002/path.1559 · Cited by 594
van de Rijn, M., Perou, C. M., Tibshirani, R., Haas, P., Kallioniemi, O., Kononen, J., Torhorst, J., Sauter, G., Zuber, M., Köchli, O. R., et al. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64476-8 · Cited by 560
Labrie, F., Luu-The, V., Labrie, C., Bélanger, A., Simard, J., Lin, S.-X., & Pelletier, G. (2003) · Endocrine Reviews · doi:10.1210/er.2001-0031 · Cited by 544 · cited 1×
“Evidence suggests that estrogens and androgens have opposing effects and that androgens may play a protective role with regard to breast tumor development”
BackgroundHugh, J., Hanson, J., Cheang, M. C. U., Nielsen, T. O., Perou, C. M., Dumontet, C., Reed, J., Krajewska, M., Treilleux, I., Rupin, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.1024 · Cited by 526
Missmer, S. A., Eliassen, A. H., Barbieri, R. L., & Hankinson, S. E. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh336 · Cited by 516
Kaaks, R., Berrino, F., Key, T., Rinaldi, S., Dossus, L., Biessy, C., Secreto, G., Amiano, P., Bingham, S., Boeing, H., et al. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji132 · Cited by 420
Niemeier, L. A., Dabbs, D. J., Beriwal, S., Striebel, J. M., & Bhargava, R. (2010) · Modern Pathology · doi:10.1038/modpathol.2009.159 · Cited by 401
Comparison of molecular phenotypes of ductal carcinoma in situand invasive breast cancer
Tamimi, R. M., Baer, H. J., Marotti, J., Galan, M., Galaburda, L., Fu, Y., Deitz, A. C., Connolly, J. L., Schnitt, S. J., Colditz, G. A., et al. (2008) · Breast Cancer Research · doi:10.1186/bcr2128 · Cited by 343
Self-citationMillar, E. K. A., Graham, P. H., O'Toole, S. A., McNeil, C. M., Browne, L., Morey, A. L., Eggleton, S., Beretov, J., Theocharous, C., Capp, A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.7075 · Cited by 314
Identification of molecular apocrine breast tumours by microarray analysis
Farmer, P., Bonnefoi, H., Becette, V, Tubiana-Hulin, M., Fumoleau, P., Larsimont, D., MacGrogan, G., Bergh, J., Cameron, D., Goldstein, D., et al. (2005) · Breast Cancer Research · doi:10.1186/bcr1122 · Cited by 307
Moinfar, F., Okcu, M., Tsybrovskyy, O., Regitnig, P., Lax, S. F., Weybora, W., Ratschek, M., Tavassoli, F. A., & Denk, H. (2003) · Cancer · doi:10.1002/cncr.11532 · Cited by 234
Agoff, M., Swanson, M., Linden, M., Hawes, P., & Lawton, M. (2003) · American Journal of Clinical Pathology · doi:10.1309/42f0-0d0d-jd0j-5edt · Cited by 211
Agoff, S. N., Swanson, P. E., Linden, H., Hawes, S. E., & Lawton, T. J. (2003) · American Journal of Clinical Pathology · doi:10.1309/42f00d0djd0j5edt · Cited by 206
Castellano, I., Allia, E., Accortanzo, V., Vandone, A. M., Chiusa, L., Arisio, R., Durando, A., Donadio, M., Bussolati, G., Coates, A. S., et al. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-0761-y · Cited by 192
Ogawa, Y., Hai, E., Matsumoto, K., Ikeda, K., Tokunaga, S., Nagahara, H., Sakurai, K., Inoue, T., & Nishiguchi, Y. (2008) · International Journal of Clinical Oncology · doi:10.1007/s10147-008-0770-6 · Cited by 184
SEX HORMONE LEVELS IN SERUM IN RELATION TO THE DEVELOPMENT OF BREAST CANCER
WYSOWSKI, D. K., COMSTOCK, G. W., HELSING, K. J., & LAU, H. L. (1987) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a114596 · Cited by 163
Naderi, A., & Hughes-Davies, L. (2008) · Neoplasia · doi:10.1593/neo.08274 · Cited by 162
Role of Androgens on MCF-7 Breast Cancer Cell Growth and on the Inhibitory Effect of Letrozole
Macedo, L. F., Guo, Z., Tilghman, S. L., Sabnis, G. J., Qiu, Y., & Brodie, A. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3984 · Cited by 158
Isola, J. J. (1993) · The Journal of Pathology · doi:10.1002/path.1711700106 · Cited by 157
González, L. O., Corte-Torres, M. D., Vázquez, J., Junquera, S., Sánchez, R., Alvarez, A. C. C., Rodrı́guez, J. C., Lamelas, M. L., & Vizoso, F. J. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-149 · Cited by 140
Gucalp, A., & Traina, T. A. (2010) · The Cancer Journal · doi:10.1097/ppo.0b013e3181ce4ae1 · Cited by 131
Sieri, S., Krogh, V., BOLELLI, G., Abagnato, C. A., Grioni, S., Pala, V. M., Evangelista, A., Allemani, C., Micheli, A., Tagliabue, G., et al. (2009) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-08-0808 · Cited by 127
Immunohistochemical categorisation of ductal carcinoma in situ of the breast
Meijnen, P., Peterse, J. L., Antonini, N. F., Rutgers, E. J. T., & van de Vijver, M. J. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6604112 · Cited by 111
Circulating Steroid Hormone Levels and Risk of Breast Cancer for Postmenopausal Women
Baglietto, L., Severi, G., English, D. R., Krishnan, K., Hopper, J. L., McLean, C., Morris, H. A., Tilley, W. D., & Giles, G. G. (2010) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-09-0532 · Cited by 109
Kuenen‐Boumeester, V., van der Kwast, T., van Putten, W. L. J., Claassen, C., Ooijen, B. V., & Henzen-Logmans, S. C. (1992) · International Journal of Cancer · doi:10.1002/ijc.2910520415 · Cited by 82
Hanley, K. Z., Wang, J., Bourne, P. A., Yang, Q., Gao, A. C., Lyman, G. H., & Tang, P. T. P. (2008) · Human Pathology · doi:10.1016/j.humpath.2007.07.007 · Cited by 62
Lillie, E. O., Bernstein, L., & Ursin, G. (2003) · Breast Cancer Research · doi:10.1186/bcr593 · Cited by 56
Estrogen and Androgen Receptors as Comediators of Breast Cancer Cell Proliferation
Toth‐Fejel, S. (2004) · Archives of Surgery · doi:10.1001/archsurg.139.1.50 · Cited by 45
A New Hormonal Therapy for Estrogen Receptor–Negative Breast Cancer
Hardin, C., Pommier, R. F., Calhoun, K. E., Muller, P., Jackson, T., & Pommier, S. J. (2007) · World Journal of Surgery · doi:10.1007/s00268-007-0694-8 · Cited by 38
Garreau, J. R., Muller, P., Pommier, R. F., & Pommier, S. J. (2006) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2006.02.004 · Cited by 16
Cited by
Garrido-Castro, A. C., Lin, N. U., & Polyak, K. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1177 · Cited by 1,451
Enzalutamide for the Treatment of Androgen Receptor–Expressing Triple-Negative Breast Cancer
Traina, T. A., Miller, K., Yardley, D. A., Eakle, J., Schwartzberg, L. S., O’Shaughnessy, J., Gradishar, W., Schmid, P., Winer, E., Kelly, C., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.3495 · Cited by 530
Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide
Cochrane, D. R., Bernales, S., Jacobsen, B. M., Cittelly, D. M., Howe, E. N., D’Amato, N. C., Spoelstra, N. S., Edgerton, S. M., Jean, A., Guerrero, J., et al. (2014) · Breast Cancer Research · doi:10.1186/bcr3599 · Cited by 427
Bonnefoi, H., Grellety, T., Tredan, O., Saghatchian, M., Dalenc, F., Mailliez, A., L'Haridon, T., Cottu, P., Abadie-Lacourtoisie, S., You, B., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw067 · Cited by 283
Metadata
- Authors
- Collins, L. C., Cole, K. S., Marotti, J. D., Hu, R., Schnitt, S. J., & Tamimi, R. M.
- Venue
- Modern Pathology
- Publisher
- Elsevier BV
- Published
- 2011-07
- Volume
- 24
- Issue
- 7
- Pages
- 924-931
- ISSN
- 0893-3952 (ISSN-L)
- OpenAlex
- W2013147142
- Cited by
- 387
- References
- 44
- FWCI
- 5.69
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.